Personalized Radiation Therapy in Cancer Pain Management

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Mar 22

PMID 30893954

Citations 8

Authors

Ewa Sierko

Dominika Hempel

Konrad Zuzda

Marek Z Wojtukiewicz

Affiliations

Soon will be listed here.

Abstract

The majority of advanced cancer patients suffer from pain, which severely deteriorates their quality of life. Apart from analgesics, bisphosphonates, and invasive methods of analgesic treatment (e.g., intraspinal and epidural analgesics or neurolytic blockades), radiation therapy plays an important role in pain alleviation. It is delivered to a growing primary tumour, lymph nodes, or distant metastatic sites, producing pain of various intensity. Currently, different regiments of radiation therapy methods and techniques and various radiation dose fractionations are incorporated into the clinical practice. These include palliative radiation therapy, conventional external beam radiation therapy, as well as modern techniques of intensity modulated radiation therapy, volumetrically modulated arch therapy, stereotactic radiosurgery or stereotactic body radiation therapy, and brachytherapy or radionuclide treatment (e.g., radium-223, strontium-89 for multiple painful osseous metastases). The review describes the possibilities and effectiveness of individual patient-tailored conventional and innovative radiation therapy approaches aiming at pain relief in cancer patients.

Citing Articles

Impacts of radiation therapy on quality of life and pain relief in patients with bone metastases.

Hoveidaei A, Karimi M, Khalafi V, Fazeli P, Hoveidaei A World J Orthop. 2024; 15(9):841-849.

PMID: 39318492 PMC: 11417628. DOI: 10.5312/wjo.v15.i9.841.

The role of ferroptosis in radiotherapy and combination therapy for head and neck squamous cell carcinoma (Review).

Feng Y, Li X, Yang B, Li M, Du Y, Wang J Oncol Rep. 2024; 51(6).

PMID: 38639185 PMC: 11056820. DOI: 10.3892/or.2024.8738.

The importance of planning CT-based imaging features for machine learning-based prediction of pain response.

Llorian-Salvador O, Akhgar J, Pigorsch S, Borm K, Munch S, Bernhardt D Sci Rep. 2023; 13(1):17427.

PMID: 37833283 PMC: 10576053. DOI: 10.1038/s41598-023-43768-6.

Evaluation of the clinical feasibility of cone-beam computed tomography guided online adaption for simulation-free palliative radiotherapy.

Kejda A, Quinn A, Wong S, Lowe T, Fent I, Gargett M Phys Imaging Radiat Oncol. 2023; 28:100490.

PMID: 37705690 PMC: 10495619. DOI: 10.1016/j.phro.2023.100490.

Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases.

Tonev D, Lalova S, Petkova-Lungova E, Timenov N, Radeva G, Kundurzhiev T Pain Res Manag. 2022; 2022:6153955.

PMID: 36479161 PMC: 9722317. DOI: 10.1155/2022/6153955.

References

Han S, Zonneberg B, de Klerk J, Quirijnen J, van het Schip A, van Dijk A . 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med. 1999; 40(4):639-42. View

Koswig S, Budach V . [Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol. 1999; 175(10):500-8. DOI: 10.1007/s000660050061. View

Steenland E, Leer J, van Houwelingen H, Post W, van den Hout W, Kievit J . The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999; 52(2):101-9. DOI: 10.1016/s0167-8140(99)00110-3. View

. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol. 1999; 52(2):111-21. View

Giannakenas C, Kalofonos H, Apostolopoulos D, Zarakovitis J, Kosmas C, Vassilakos P . Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol. 2000; 23(1):83-8. DOI: 10.1097/00000421-200002000-00023. View

Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J . Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2001; 27(2):123-30. DOI: 10.1007/s002590050017. View

Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini C . Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med. 2000; 41(4):647-54. View

Hoskin P, Stratford M, Folkes L, Regan J, Yarnold J . Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000; 355(9213):1428-9. DOI: 10.1016/s0140-6736(00)02144-9. View

Liepe K, Hliscs R, Kropp J, Gruning T, Runge R, Koch R . Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radiopharm. 2000; 15(3):261-5. DOI: 10.1089/108497800414356. View

10.

Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C . Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med. 2000; 41(10):1689-94. View

11.

Fuster D, Herranz R, Alcover J, Mateos J, Martin F, Vidal-Sicart S . [Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm]. Rev Esp Med Nucl. 2000; 19(4):270-4. DOI: 10.1016/s0212-6982(00)71874-x. View

12.

Turner S, Gruenewald S, Spry N, Gebski V . Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001; 84(3):297-302. PMC: 2363737. DOI: 10.1054/bjoc.2000.1610. View

13.

Serafini A . Therapy of metastatic bone pain. J Nucl Med. 2001; 42(6):895-906. View

14.

Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S . Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001; 66(2):101-9. DOI: 10.1023/a:1010658522847. View

15.

Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, PIFFANELLI A . A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001; 28(7):788-98. DOI: 10.1007/s002590100533. View

16.

Ashayeri E, Omogbehin A, Sridhar R, Shankar R . Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc. 2002; 94(8):706-11. PMC: 2594277. View

17.

Han S, de Klerk J, Tan S, van het Schip A, Derksen B, van Dijk A . The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med. 2002; 43(9):1150-6. View

18.

van den Hout W, van der Linden Y, Steenland E, Wiggenraad R, Kievit J, de Haes H . Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst. 2003; 95(3):222-9. DOI: 10.1093/jnci/95.3.222. View

19.

Wang R, Zhang C, Zhu S, Zhu M . A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract. 2003; 12(2):97-101. DOI: 10.1159/000069120. View

20.

Silberstein E, Taylor Jr A . EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2003; 30(3):BP7-11. DOI: 10.1007/s00259-002-1057-1. View